AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Radiation: [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL)Drug: AZD9833 Oral SolutionDrug: AZD9833 film-coated tablet B Dose 1Drug: AZD9833 film-coated tablet A Dose 2Drug: AZD9833 film-coated tablet B Dose 2Drug: AZD9833 film-coated tablet A Dose 1
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT04546347
- Locations
- π¬π§
Research Site, Ruddington, United Kingdom
A Study of Benralizumab in Patients With Eosinophilic Esophagitis
Phase 3
Terminated
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Biological: Matching placeboBiological: Benralizumab
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 211
- Registration Number
- NCT04543409
- Locations
- π¬π§
Research Site, London, United Kingdom
A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT04541433
- Locations
- π―π΅
Research Site, Koto-ku, Japan
AZD1222 Vaccine for the Prevention of COVID-19
Phase 3
Withdrawn
- Conditions
- COVID-19
- Interventions
- Biological: AZD1222
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT04540393
- Locations
- π·πΊ
Research Site, St. Petersburg, Russian Federation
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 245
- Registration Number
- NCT04538742
- Locations
- π¬π§
Research Site, Buckhurst Hill, United Kingdom
Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3520
- Registration Number
- NCT04536402
- Locations
- π¨π³
Research Site, Zibo, China
Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers
Phase 1
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT04532918
- Locations
- π©πͺ
Research Site, Berlin, Germany
Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 342
- Registration Number
- NCT04532645
- Locations
- π¬π§
Research Site, Swansea, United Kingdom
Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 106
- Registration Number
- NCT04529564
- Locations
- π¨π³
Chang Gung Medical Foundation-Kaohsiung Branch, Kaohsiung, Taiwan
π¨π³Chang Gung Medical Foundation-Keelung Branch, Keelung, Taiwan
π¨π³China Medical University Hospital, Taichung, Taiwan
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
Phase 3
Completed
- Conditions
- COVID-19SARS-CoV-2
- Interventions
- Biological: PlaceboBiological: AZD1222
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32450
- Registration Number
- NCT04516746
- Locations
- π΅πͺ
Research Site, Lima, Peru
Β© Copyright 2025. All Rights Reserved by MedPath